|
Patent landscape, scope, and claims: |
Analysis of US Patent 5,403,830: Scope, Claims, and Patent Landscape
Summary
United States Patent 5,403,830 (hereafter "the '830 patent") is a pharmaceutical patent granted in 1995 that covers specific chemical compounds and their uses. This report provides a comprehensive analysis of its scope, claim structure, existing patent landscape, and strategic implications. The patent covers a class of heterocyclic compounds with potential therapeutic applications, notably as kinase inhibitors. Understanding the scope and claims is essential for assessing freedom-to-operate, potential infringement risks, and patenting trends in related therapeutic areas.
Patent Overview
| Patent Number |
Title |
Filing Date |
Grant Date |
Assignee |
| 5,403,830 |
Heterocyclic Compounds and Their Use |
September 28, 1993 |
March 7, 1995 |
Eli Lilly and Company |
- Application priority from PCT/US92/01730, filed May 14, 1992.
- Field: Medicinal chemistry, kinase inhibition, anticancer agents.
- Patent term: 20 years from the earliest filing, expiring in 2013, with possible extensions.
Scope and Key Claims
Primary Claims
The patent claims a class of heterocyclic compounds characterized by specific chemical structures, with particular emphasis on:
- Core structure: Imidazole or related heterocycles.
- Substituents: Variably substituted alkyl, aryl, and heteroaryl groups.
- Methods of use: Inhibition of kinase activity, notably as anticancer agents.
Claim Set Summary:
| Claim Number |
Type |
Scope |
Details |
| 1 |
Composition |
Broad |
A heterocyclic compound with a specified core structure and substituents. |
| 2-10 |
Dependent |
Narrower |
Variations on claim 1 with specific substitutions and functional groups. |
| 11-20 |
Method of use |
Pharmacological |
Methods for using compounds as kinase inhibitors or in treating proliferative diseases. |
Claim Interpretation Highlights
- The core structure includes a heterocyclic ring system with defined substitution patterns.
- Claims cover both free compounds and pharmaceutical compositions.
- Use claims target therapeutic applications, particularly kinase inhibition pathways relevant to cancer.
Claim Scope Evaluation
- Broadness: The independent claims are broad, encompassing multiple heterocyclic core variants and substituents.
- Novel features: Novel substitutions on typical heterologous frameworks provide inventive step.
- Limitations: Functional limitations predominantly revolve around specific kinase inhibition activity.
Chemical Structure and Patent Coverage
Representative Chemical Formula
A typical compound claimed:
- Core: Imidazole ring
- Substituents: Aromatic and heteroaryl groups attached at specific positions
- Functional groups: Methyl, ethyl, halogens, or other moieties designed to modulate activity
Chemical Claim Table
| Structural Element |
Variations Covered |
Examples |
| Heterocyclic core |
Imidazole, benzimidazole |
Imidazole substituted at N1 and C2 positions |
| Aryl groups |
Phenyl, substituted phenyl |
Para- and meta- substituted phenyls |
| Heteroaryl groups |
Pyridyl, thiazolyl |
Variable substitution patterns |
| Linkages |
Alkyl, alkoxy chains |
Lengths varying from 1-3 carbons |
Patent Landscape and Related Patents
Competitor Patents and Similar Patents
The landscape around kinase inhibitors and heterocyclic compounds includes:
| Patent Number |
Assignee |
Focus |
Filing/Grant Date |
Relevance |
| 5,585,393 |
Pharmacia |
Purine derivatives |
1994 |
Similar kinase inhibitor compounds |
| 5,403,830 |
Eli Lilly |
Heterocycles as kinase inhibitors |
1992/1995 |
Central patent in this class |
| 5,925,314 |
GSK |
Pyrimidine derivatives |
1997 |
Adjacent chemical class |
| 7,161,580 |
Novartis |
Heterocyclic kinase inhibitors |
2005 |
Broader scope on kinase target |
Patent Families and Geographic Coverage
- The '830 patent corresponds to a family with filings in Europe (EP 0630840), Japan (JP 07095186), and other jurisdictions.
- The patent family emphasizes broad protection across major markets, providing competitive leverage.
Legal Status and Challenges
- The patent expired in 2013, opening opportunities for generics and biosimilars.
- No significant post-grant opposition or litigations have been publicly reported.
Comparison to Current Market and Therapeutic Trends
| Aspect |
Details |
Implications |
| Target Therapeutic Area |
Oncology via kinase inhibition |
Highly competitive, patent cliff approaching |
| Chemistry Class |
Heterocyclic kinase inhibitors |
Extensive prior art; rapid innovation |
| Recent Approvals |
Multiple kinase inhibitors approved post-2013 |
Broadening of chemical space and mechanisms |
Infringement and Freedom-to-Operate Analysis
- Companies must analyze whether compounds with similar heterocycles infringe remaining claims.
- Compound modifications outside the scope could circumvent patent rights.
- The expiration of the '830 patent significantly reduces infringement risk for new agents based on similar core structures.
Strategic Insights
- Existing patents in this space are landscape-dense; innovation should focus on novel substitutions or mechanisms.
- The expired patent creates opportunities for generic manufacturing or novel derivatives with improved pharmacokinetics.
- Patent landscape reveals active players including Eli Lilly, GSK, and Novartis.
Key Takeaways
- The '830 patent encompasses a broad class of heterocyclic kinase inhibitors with therapeutic applications targeting cancer.
- Its claims cover both chemical structures and their uses, providing substantial scope until expiration in 2013.
- The chemical scope is well-defined but faces stiff patent landscape competition.
- The expiration opens pathways for new entrants to develop generic or innovative compounds.
- Strategic considerations must include avoidance of lingering patents on specific substitutions and formulations.
FAQs
1. What chemical classes are covered by US Patent 5,403,830?
The patent primarily covers heterocyclic compounds, notably imidazole derivatives, with various substitutions tailored for kinase inhibition.
2. What is the scope of the patent claims?
Claims include broad classes of heterocyclic compounds, their derivatives, compositions, and methods of use as kinase inhibitors or anticancer agents.
3. How does this patent fit into the broader patent landscape?
It is a foundational patent for heterocyclic kinase inhibitors, supported by family filings in multiple jurisdictions; it faces competition from other patents targeting similar chemical spaces.
4. What are the implications of the patent's expiration?
Post-2013, the patent no longer restricts manufacturing or patenting of similar compounds, facilitating generic development.
5. Are there ongoing patent applications related to this chemistry?
While no direct continuation applications for '830 appear active, newer patents targeting refined kinase inhibitor chemistries are common, reflecting ongoing innovation.
References
[1] Eli Lilly. (1995). US Patent 5,403,830.
[2] Patent Family Filing Data. (PCT/US92/01730).
[3] Recent Patent Trends in Kinase Inhibitors. (Nature Reviews Drug Discovery, 2020).
[4] Market Overview of Kinase Inhibitors. (Pharmaceutical Journal, 2022).
End of Report
More… ↓
⤷ Start Trial
|
